CORONA Remedies Limited has informed the Exchange about change in ManagementAppointment of M/s. Shah & Shah Associates, Chartered Accountants as Internal Auditor of the Company for the Financial Year 2026-27
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies Limited held a Board Meeting on May 11, 2026, approving audited financial results for Q4 and FY 2026. Standalone revenue from operations grew 17.3% year-on-year to Rs. 1,403.18 Crores, while Net Profit after Tax increased 24% to Rs. 184.85 Crores. EPS stood at Rs. 30.22 vs Rs. 24.37 in the prior year. The Board recommended a final dividend of Rs. 10 per share (100% payout) with record date June 19, 2026. Multiple auditor appointments were approved including new statutory auditor Walker Chandiok & Co LLP (5-year term), re-appointment of secretarial auditor Dhara Patel, internal auditor Shah & Shah Associates for FY 2026-27, and cost auditor Manish B. Analkat. Dr. Kirtikumar Mehta was recommended for re-appointment as Non-Executive Chairman for 5 years from April 2027. The company listed on NSE and BSE in December 2025 via an IPO.
Strong financial performance with ~24% profit growth and maiden dividend recommendation signal positive shareholder returns. The appointment of a Big 4 firm (Walker Chandiok) as statutory auditor reflects good governance standards. No adverse signals detected for investors.